R3 Stem Cell CEO publishes paper on regenerative approach for athlete soft tissue injuries

R3 Stem Cell founder and CEO Dr. David Greene has published a peer-reviewed paper in Cureus on a combined biologic protocol for tendon, ligament and muscle injuries in athletes. The paper argues that the approach may improve recovery and return-to-sport outcomes by pairing stem cells, PRP and exosomes.

Why it matters: - Soft tissue injuries can sideline athletes for games, seasons or entire careers. - The paper argues that standard care often manages symptoms without repairing tissue at a biological level. - R3 Stem Cell is positioning a combined biologic protocol as a different approach to healing and return to sport.

What happened: - Dr. David Greene, founder and CEO of R3 Stem Cell, published a peer-reviewed paper in the Cureus Journal of Medical Science. - The paper is titled “Regenerative Trifecta: A Multimodal Regenerative Approach to Soft Tissue Injury Recovery and Return to Sport.” - Cureus published the paper on Aug. 16, 2026 in Volume 18, Issue 8. - The paper has DOI 10.7759/cureus.114620.

The details: - The paper focuses on athletic tendon, ligament and muscle injuries. - The Regenerative Trifecta combines umbilical cord mesenchymal stem cells, platelet-rich plasma and exosomes. - R3 Stem Cell developed the protocol to address the underlying biology of soft tissue healing rather than symptoms alone. - R3 Stem Cell says the Regenerative Trifecta is available only at its global Centers of Excellence. - The paper says tendons and ligaments are poorly vascularized and often heal with fibrotic scar tissue instead of true collagen restoration. - The paper says that can leave repaired tissue mechanically weaker and more prone to re-injury. - The paper says existing clinical and preclinical evidence supports mesenchymal stem cells, PRP and extracellular vesicles as tools that may improve the injury environment and healing quality. - The paper outlines the mechanism of action for each component and the rationale for combining them. - The paper gives special attention to elite and masters-level athletes. - The paper is publicly available in Cureus.

Between the lines: - The publication gives R3 Stem Cell a peer-reviewed platform for a treatment model the company already offers. - Greene’s comments frame the protocol as a response to limits in rest, physical therapy and anti-inflammatory care. - Greene said the company has treated many Olympians and athletes from the NBA, MLB, NFL and NCAA. - Greene also said the combined effect may help athletes return to sport faster than conventional treatment, adding that the claim is based on years of anecdotal evidence. - The paper adds to the company’s effort to build clinical support for regenerative biologic therapies.

What's next: - R3 Stem Cell is likely to continue marketing the Regenerative Trifecta through its Centers of Excellence. - The company says it will keep advancing the evidence base through research and publication. - Athletes and active patients seeking the protocol would need access through R3 Stem Cell's treatment network.

The bottom line: - R3 Stem Cell is using peer-reviewed research to support a bundled regenerative therapy aimed at faster recovery from sports-related soft tissue injuries.